PDCD1 and head and neck squamous cell carcinoma: However, the validation performed with only 25 R/M HNSCC potentially eligible for PD-1/PD-L1-targeted therapy regimens can provide only proof of the principle for utilizing BN as CDSS supporting the decision-making process.